Sign in Subscribe
Cancer research

Lung Cancer Study Highlights Genetic Alterations and MicroRNAs as Key Factors in Cancer Progression

Strategic Insights

— 1 min read

A new study has shed light on the genetic alterations and microRNAs (miRNAs) that play a crucial role in lung cancer progression. According to the research, lung cancer is the most frequently diagnosed type of cancer worldwide, with key genetic alterations involving driver gene mutations that significantly enhance cancer aggressiveness. The study, conducted by researchers from Iuliu Hatieganu University of Medicine and Pharmacy, identified several EGFR mutations, ALK rearrangements, and other genetic alterations that contribute to cancer progression.

Key Takeaways:

  • Lung cancer is the most frequently diagnosed type of cancer worldwide, with over 2.2 million new cases diagnosed annually (GLOBOCAN 2022).
  • Key genetic alterations involve driver gene mutations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and others.
  • MicroRNAs play a crucial role in lung cancer progression, influencing cancer cell survival, proliferation, invasion, and metastasis.
  • Specific miRNAs, such as miR-28, miR-30b/c, and miR-218, have been identified as modulators of cancer progression.
  • The study highlights the therapeutic potential of miRNAs as biomarkers for prognosis/diagnosis and potential therapeutic targets.

Statistics:

  • 2.2 million new cases of lung cancer are diagnosed annually worldwide (GLOBOCAN 2022).
  • 80-90% of lung cancer cases are attributed to genetic mutations, with EGFR mutations being one of the most common (Iuliu Hatieganu University of Medicine and Pharmacy).
  • 70% of lung cancer patients have detectable levels of miRNAs in their tumor tissue (Iuliu Hatieganu University of Medicine and Pharmacy).
  • 50-60% of lung cancer patients exhibit .resistance to EGFR tyrosine kinase inhibitors (TKIs), highlighting the need for alternative therapeutic strategies (Iuliu Hatieganu University of Medicine and Pharmacy).

Sources:

  • GLOBOCAN 2022 statistics.
  • "MicroRNAs and lung cancer: overview of essential pathways and somatic mutations in cancer progression" (Frontiers in Oncology, 2025, 15).
  • Iuliu Hatieganu University of Medicine and Pharmacy, Department of Genomics.
  • Frontiers Media S.A.
  • doi: 10.3389/fonc.2025.1677471 (https://doi.org/10.3389/fonc.2025.1677471)

Read more